利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.054 秒)

    Humanized PAI-1 antibodies
    22.
    发明授权
    Humanized PAI-1 antibodies 有权
    人源化PAI-1抗体

    公开(公告)号：US07771720B2

    公开(公告)日：2010-08-10

    申请号：US12205760

    申请日：2008-09-05

    申请人： Donald E. Staunton ,  Maximiliano Vasquez

    发明人： Donald E. Staunton ,  Maximiliano Vasquez

    IPC分类号： A61K39/395 ,  C12P21/08

    CPC分类号： C07K16/36 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76

    摘要： The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.

    摘要翻译： 本申请涉及将PAI-1转化为其潜在形式的人源化抗PAI-1抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及通过将PAI-1转化为其潜在形式或增加蛋白水解切割而结合和中和PAI-1的抗体。 另一方面涉及抑制或中和PAI-1用于检测，诊断或治疗与PAI-1或其组合相关的疾病或病症的人源化抗体的用途。

    Humanized PAI-1 antibodies
    29.
    发明授权
    Humanized PAI-1 antibodies 有权
    人源化PAI-1抗体

    公开(公告)号：US07981415B2

    公开(公告)日：2011-07-19

    申请号：US12274793

    申请日：2008-11-20

    申请人： Donald E. Staunton ,  Maximiliano Vasquez

    发明人： Donald E. Staunton ,  Maximiliano Vasquez

    IPC分类号： A61K39/395

    CPC分类号： C07K16/38 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56

    摘要： The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.

    摘要翻译： 本申请涉及将PAI-1转化为其潜在形式的人源化抗PAI-1抗体及其抗原结合片段的组合物。 一个方面涉及在可变重链，可变轻链或两者的至少一个框架区的至少一个氨基酸残基中具有一个或多个修饰的抗体。 另一方面涉及通过将PAI-1转化为其潜在形式或增加蛋白水解切割而结合和中和PAI-1的抗体。 另一方面涉及抑制或中和PAI-1用于检测，诊断或治疗与PAI-1或其组合相关的疾病或病症的人源化抗体的用途。